Antisense technology: an emerging platform for cardiovascular disease therapeutics

Area of Science:

• Biotechnology
• Pharmacology
• Cardiovascular Medicine

Background:

• Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are nucleic acid-based therapies that inhibit gene expression at the translational level.
• Significant advancements in antisense technology over 25 years have paved the way for their therapeutic application in various diseases.
• Cardiovascular disease remains a leading cause of mortality, necessitating novel therapeutic strategies.

Purpose of the Study:

• To provide a historical overview of antisense technology development.
• To review the clinical progression of mipomersen, a landmark cardiovascular antisense therapeutic.
• To update on the current status of other antisense-based therapeutics for cardiovascular diseases.

Main Methods:

• Literature review of preclinical and clinical studies on antisense oligonucleotides and small interfering RNAs.
• Analysis of regulatory approval processes for cardiovascular antisense drugs.
• Examination of ongoing clinical trials for novel antisense therapeutics.

Main Results:

• Mipomersen, targeting hepatic apolipoprotein B mRNA, received FDA approval as the first chronically administered cardiovascular antisense therapeutic.
• The review highlights the successful translation of antisense technology from bench to bedside.
• Several other cardiovascular antisense therapeutics are currently in various stages of clinical development.

Conclusions:

• Antisense technology represents a powerful and evolving therapeutic approach for cardiovascular disease.
• The success of mipomersen validates the potential of mRNA-targeting drugs in managing cardiovascular risk factors.
• Continued research and development in antisense therapeutics promise new treatment options for patients with cardiovascular conditions.